RxDoctor Payments Data

George Nahhas, MD

Cardiovascular Disease · Dearborn, MINPI 1427084805

Payments from drug & device makers

$8,364in general payments, 2019–2025

Across 352 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$1K
  • Johnson & Johnson$485
  • E.r. Squibb & Sons, L.L.C.$468
  • Boehringer Ingelheim$432
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$422
  • plus $4K from 42 others

What the payments were for

  • Travel & lodging$85310%
  • Food & beverage$7,32588%
  • Education$1862%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,364 in reported general payments places this provider in the 65th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$538,778
Medicare patients
967
Services billed
5,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban456$472,481
XareltoRivaroxaban129$139,844
CamzyosMavacamten16$107,594
EntrestoSacubitril/Valsartan110$107,448
MultaqDronedarone Hcl68$100,716
Repatha SureclickEvolocumab24$33,522
Repatha SyringeEvolocumab35$21,890
BrilintaTicagrelor26$17,387
JardianceEmpagliflozin12$15,741
Metoprolol Succinate752$12,045
FarxigaDapagliflozin Propanediol11$10,465
ClopidogrelClopidogrel Bisulfate468$7,945
Atorvastatin Calcium516$5,887
Carvedilol357$4,192
Losartan Potassium334$4,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$283$472,481456 claims
Johnson & JohnsonXarelto$485$139,844129 claims
E.r. Squibb & Sons, L.L.C.Camzyos$468$107,59416 claims
NovartisEntresto$337$107,448110 claims
Sanofi-aventis U.S. LLCMultaq$40$100,71668 claims
AstraZenecaBrilinta, Farxiga$361$27,85237 claims
Boehringer IngelheimJardiance$432$15,74112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →